Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

NCT01092065 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: AFQ056 with L-dopa
DRUG: Placebo

Sponsor

Novartis